MedTrace Logo

MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis

NCT00495339 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2009-03-04

No results posted yet for this study

Summary

Estimate of clinical and microbiological efficacy of Levofloxacin (Tavanic) in combine therapy of MDR TB.

Estimate of safety of Levofloxacin (Tavanic) in combine therapy of MDR TB.

Conditions

  • Tuberculosis, Pulmonary

Interventions

DRUG

Levofloxacin

500-1000 mg once a day daily per os with combination of drugs.

Sponsors & Collaborators

Principal Investigators

  • Marina Atarshchikova · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-04-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00495339 on ClinicalTrials.gov